Previous 10 | Next 10 |
The FDA has signed off AlloVir's ( ALVR +6.0% ) Investigational New Drug application (IND) for ALVR109, an allogeneic, off-the-shelf virus-specific T cell therapy candidate against SARS-CoV-2. More news on: AlloVir, Inc., Healthcare stocks news, Stocks on the move, Read m...
- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients - Proof-of-concept clinical trial with ALVR109 to begin in Q42020 CAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALV...
CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced the appointment of Ercem Atillasoy, M.D., as the company’s Chief Regulatory and Safety Officer, a newly created position. Dr. Atillasoy brings nearly 25 ...
I have been specializing myself in the insider topic with months of empirical research to understand the trades and their informativeness. Insiders are the high managers, directors and majority shareholders of a firm and know their company better than anyone else as they are close to the s...
AlloVir (NASDAQ: ALVR ) : Q2 GAAP EPS of -$4.43 misses by $4.12 . Cash, cash equivalents, and marketable securities of $104.5M. Press Release More news on: AlloVir, Inc., Earnings news and commentary, Healthcare stocks news,
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2020. “AlloVir has achieved important scientific and operational milestones that have us ...
CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley 18 th Annual Global Healthcare Conference on September 17, 2020 at 5:00 p.m. ET. A live webcast o...
Two IPOs and two SPACs are scheduled to go public in the week ahead. Chinese EV maker Xpeng (XPEV) is leading summer's last wave with a billion-dollar deal. Xpeng plans to raise $1.0 billion at an $8.8 billion market cap. Xpeng targets the mid- to high-end segment in China's passenger vehicl...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the closing of its upsized initial public offering of 18,687,500 shares of common stock, which includes the exercise in full of the underwriters ...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...